Alector launches $208m fundraiser for Alzheimer’s R&D with AbbVieAlector has launched an $208 million stock market offering as it ramps up clinical trials with AbbVie into Share XAlector launches $208m fundraiser for Alzheimer’s R&D with AbbViehttps://pharmaphorum.com/news/alector-launches-208m-fundraiser-as/
Alector kicks off biotech IPOs after US government shutdownThe 35-day US government shutdown has not just played havoc at government-run agencies – it has had a Share XAlector kicks off biotech IPOs after US government shutdownhttps://pharmaphorum.com/news/alector-kicks-off-biotech-ipos-after-us-government-shutdown/
AbbVie signs $225m ‘immunoneurology’ deal to tackle Alzheimer’sPartnership will use novel approach to treating Alzheimer’s. Share XAbbVie signs $225m ‘immunoneurology’ deal to tackle Alzheimer’shttps://pharmaphorum.com/news/abbvie-immunoneurology-alzheimers/